Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 2
2014 1
2015 3
2016 1
2020 1
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.
Pavlides M, Mózes FE, Akhtar S, Wonders K, Cobbold J, Tunnicliffe EM, Allison M, Godfrey EM, Aithal GP, Francis S, Romero-Gomez M, Castell J, Fernandez-Lizaranzu I, Aller R, González RS, Agustin S, Pericàs JM, Boursier J, Aube C, Ratziu V, Wagner M, Petta S, Antonucci M, Bugianesi E, Faletti R, Miele L, Geier A, Schattenberg JM, Tilman E, Ekstedt M, Lundberg P, Berzigotti A, Huber AT, Papatheodoridis G, Yki-Järvinen H, Porthan K, Schneider MJ, Hockings P, Shumbayawonda E, Banerjee R, Pepin K, Kalutkiewicz M, Ehman RL, Trylesinksi A, Coxson HO; LITMUS Consortium Investigators; Martic M, Yunis C, Tuthill T, Bossuyt PM, Anstee QM, Neubauer S, Harrison S. Pavlides M, et al. Among authors: antonucci m. Contemp Clin Trials. 2023 Nov;134:107352. doi: 10.1016/j.cct.2023.107352. Epub 2023 Oct 4. Contemp Clin Trials. 2023. PMID: 37802221 Free article.
Curative therapies for hepatocellular carcinoma: an update and perspectives.
Sacco R, Antonucci M, Bresci G, Corti A, Giacomelli L, Mismas V, Rainieri M, Romano A, Eggenhoffner R, Tumino E, Cabibbo G. Sacco R, et al. Among authors: antonucci m. Expert Rev Anticancer Ther. 2016;16(2):169-75. doi: 10.1586/14737140.2016.1123625. Epub 2015 Dec 14. Expert Rev Anticancer Ther. 2016. PMID: 26588992 Review.
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G, Tremosini S, Galati G, Mazza G, Gadaleta-Caldarola G, Lombardi G, Antonucci M, Sacco R. Cabibbo G, et al. Among authors: antonucci m. Expert Rev Anticancer Ther. 2014 Jul;14(7):831-45. doi: 10.1586/14737140.2014.920694. Epub 2014 May 22. Expert Rev Anticancer Ther. 2014. PMID: 24850249 Review.
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.
Giuffrida P, Celsa C, Antonucci M, Peri M, Grassini MV, Rancatore G, Giacchetto CM, Cannella R, Incorvaia L, Corsini LR, Morana P, La Mantia C, Badalamenti G, Brancatelli G, Cammà C, Cabibbo G. Giuffrida P, et al. Among authors: antonucci m. Biomedicines. 2022 Nov 6;10(11):2827. doi: 10.3390/biomedicines10112827. Biomedicines. 2022. PMID: 36359347 Free PMC article. Review.
Multimodal approaches to the treatment of hepatocellular carcinoma.
Cabibbo G, Latteri F, Antonucci M, Craxì A. Cabibbo G, et al. Among authors: antonucci m. Nat Clin Pract Gastroenterol Hepatol. 2009 Mar;6(3):159-69. doi: 10.1038/ncpgasthep1357. Epub 2009 Feb 3. Nat Clin Pract Gastroenterol Hepatol. 2009. PMID: 19190599 Review.
15 results